{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:50:13Z","timestamp":1776693013822,"version":"3.51.2"},"update-to":[{"DOI":"10.1002\/14651858.cd007545","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T00:00:00Z","timestamp":1372982400000}}],"reference-count":159,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007545.pub2","type":"journal-article","created":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T12:14:02Z","timestamp":1373026442000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB"],"prefix":"10.1002","volume":"2013","author":[{"given":"Surendra K","family":"Sharma","sequence":"first","affiliation":[{"name":"All India Institute of Medical Sciences; Department of Medicine; Room 3097, Teaching Block Ansari Nagar New Delhi India 110029"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anju","family":"Sharma","sequence":"additional","affiliation":[{"name":"Indian Council of Medical Research; Division of Publication & Information; V. Ramalingaswami Bhawan Post Box 4911 New Delhi India 110029"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamilarasu","family":"Kadhiravan","sequence":"additional","affiliation":[{"name":"Jawaharlal Institute of Postgraduate Medical Education and Research; Department of Medicine; Dhanvantri Nagar Puducherry India 605006"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prathap","family":"Tharyan","sequence":"additional","affiliation":[{"name":"Christian Medical College; South Asian Cochrane Network & Centre, Prof. BV Moses & ICMR Advanced Centre for Research & Training in Evidence Informed Health Care; Carman Block II Floor CMC Campus, Bagayam Vellore Tamil Nadu India 632002"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,7,5]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD007545.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5588\/ijtld.11.0504","article-title":"Latent\u00a0tuberculosis infection treatment for prison inmates: a randomised controlled trial","volume":"16","author":"Chan","year":"2012","journal-title":"International Journal of Tuberculosis and Lung Diseases"},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","article-title":"A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong","volume":"145","author":"Hong Kong Chest Service\/Tuberculosis Research Centre","year":"1992","journal-title":"The American Review of Respiratory Disease"},{"issue":"6","key":"10.1002\/14651858.CD007545.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1378\/chest.124.6.2112","article-title":"Initial experience on rifampin and pyrazinamide versus isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong","volume":"124","author":"Leung","year":"2003","journal-title":"Chest"},{"issue":"10","key":"10.1002\/14651858.CD007545.pub2-BIB0004|cit4","first-page":"761","article-title":"[Compliance and tolerance of new antitubercular short-term chemopreventive regimens in childhood--a pilot project]","volume":"48","author":"Magdorf","year":"1994","journal-title":"Pneumologie (Stuttgart, Germany)"},{"issue":"11","key":"10.1002\/14651858.CD007545.pub2-BIB0005|cit5","first-page":"401","article-title":"[Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis]","volume":"111","author":"Martinez Alfaro","year":"1998","journal-title":"Medicina clinica"},{"issue":"4","key":"10.1002\/14651858.CD007545.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0007|cit7","first-page":"A101","article-title":"Rifampin versus isoniazid for treatment of latent tuberculosis: A cost-effectiveness analysis based on a multicenter clinical trial","volume":"179","author":"Esfahani","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"10","key":"10.1002\/14651858.CD007545.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with four months of rifampin therapy or nine months of isoniazid therapy for latent tuberculosis infection: a randomized trial","volume":"149","author":"Menzies","year":"2008","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0009|cit9","unstructured":"Trajman A Zylberberg D Dion MJ Al-Otaibi B Long R Oliveira AA Poster 46: 91161 Factors associated with treatment completion in a randomized trial of treatment of latent TB infection Programme of the 5th Conference of The Union Europe Region, \u00a0Dubrovnik, Croatia, 27-30 May 2009; http:\/\/www.theunion.org\/index.php\/conferences\/index.php?option=com_flexicontent&view=items&id=81&Itemid=36 131"},{"issue":"2","key":"10.1002\/14651858.CD007545.pub2-BIB0010|cit10","first-page":"57","article-title":"[Treatment of latent tuberculosis among homeless population. Comparison between two therapeutic approaches]","volume":"122","author":"Sanchez-Arcilla","year":"2004","journal-title":"Medicina clinica"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0011|cit11","first-page":"A4041","article-title":"Hepatitis C virus infection and female sex are risk factors for treatment limiting hepatotoxicity in a large clinical trial of treatment of latent tuberculosis infection: results of a nested case-control study","volume":"183","author":"Bliven-Sizemore","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0012|cit12","unstructured":"CDC fact sheet PREVENT TB study http:\/\/www.cdc.gov\/nchhstp\/newsroom\/docs\/PREVENT-TB-Factsheet.pdf 2011 1-2 (accessed 01 March 2012)"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0013|cit13","unstructured":"Sterling T Villarino E TBTC study 26: weekly Rifapentine + INH for 3 months vs. daily INH for 9 months for the treatment of LTBI http:\/\/clinicaltrials.gov\/show\/NCT00023452"},{"issue":"23","key":"10.1002\/14651858.CD007545.pub2-BIB0014|cit14","first-page":"1","article-title":"A study of the effectiveness and tolerability of weekly Rifapentine\/Isoniazid for three months versus daily Isoniazid for nine months for the treatment of latent tuberculosis infection, Version 12_19_06 (Study Protocol: US Public Health Service Study 26)","volume":"365","author":"Sterling","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"10.1002\/14651858.CD007545.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis\u00a0infection","volume":"365","author":"Sterling","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007545.pub2-BIB0016|cit16","first-page":"706","article-title":"Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficency virus? Erratum","volume":"9","author":"Tortajada","year":"2005","journal-title":"International Journal of Tuberculosis and Lung Diseases"},{"issue":"3","key":"10.1002\/14651858.CD007545.pub2-BIB0017|cit17","first-page":"276","article-title":"Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?","volume":"9","author":"Tortajada","year":"2005","journal-title":"The International Journal of Tuberculosis and Lung Disease"},{"issue":"2","key":"10.1002\/14651858.CD007545.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-81-2-200","article-title":"The effect of isoniazid on transaminase levels","volume":"81","author":"Bailey","year":"1974","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD007545.pub2-BIB0019|cit19","first-page":"1014","article-title":"Tuberculosis prevention project","volume":"84","author":"Barnwell","year":"1992","journal-title":"Journal of the National Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD007545.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0376-8716(01)00208-3","article-title":"A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users","volume":"66","author":"Batki","year":"2002","journal-title":"Drug and Alcohol Dependence"},{"issue":"24","key":"10.1002\/14651858.CD007545.pub2-BIB0021|cit21","first-page":"1553","article-title":"Chemoprophylaxis: a major adjunct in the prevention of tuberculosis","volume":"66","author":"Bridge","year":"1967","journal-title":"Michigan Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007545.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archinte.1977.03630210016007","article-title":"Isoniazid chemoprophylaxis. Association with detection and incidence of liver toxicity","volume":"137","author":"Byrd","year":"1977","journal-title":"Archives of internal medicine"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0023|cit23","unstructured":"Infection fighters. Maintenance therapy for TB works Treatment Update 2001 1 2"},{"issue":"8","key":"10.1002\/14651858.CD007545.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0002-9343(01)00695-7","article-title":"A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users","volume":"110","author":"Chaisson","year":"2001","journal-title":"The American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007545.pub2-BIB0025|cit25","first-page":"703","article-title":"Predicting completion of treatment among foreign-born adolescents treated for latent tuberculosis infection in Los Angeles","volume":"8","author":"Coly","year":"2004","journal-title":"The International Journal of Tuberculosis and Lung Disease"},{"issue":"6","key":"10.1002\/14651858.CD007545.pub2-BIB0026|cit26","first-page":"935","article-title":"A controlled trial of community-wide isoniazid prophylaxis in Alaska","volume":"95","author":"Comstock","year":"1967","journal-title":"The American Review of Respiratory Disease"},{"issue":"5","key":"10.1002\/14651858.CD007545.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/00039896.1972.10666182","article-title":"Preventive treatment of untreated, nonactive tuberculosis in an Eskimo population","volume":"25","author":"Comstock","year":"1972","journal-title":"Archives of Environmental Health"},{"issue":"2","key":"10.1002\/14651858.CD007545.pub2-BIB0028|cit28","first-page":"195","article-title":"Isoniazid prophylaxis among Alaskan Eskimos: a progress report","volume":"110","author":"Comstock","year":"1974","journal-title":"The American Review of Respiratory Disease"},{"issue":"3","key":"10.1002\/14651858.CD007545.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0962-8479(96)90007-6","article-title":"Short course chemoprophylaxis with rifampicin, isoniazid and pyrazinamide for tuberculosis evaluated in gold miners with chronic silicosis: a double-blind placebo controlled trial","volume":"77","author":"Cowie","year":"1996","journal-title":"Tuberclosis and Lung Disease"},{"issue":"2","key":"10.1002\/14651858.CD007545.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ije\/2.2.153","article-title":"Isoniazid chemoprophylaxis of latent primary tuberculosis: in five trial centres in France from 1959 to 1969","volume":"2","author":"Debre","year":"1973","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD007545.pub2-BIB0031|cit31","first-page":"419","article-title":"The use of isoniazid among household contacts of open cases of pulmonary tuberculosis","volume":"33","author":"Egsmose","year":"1965","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0032|cit32","first-page":"112","article-title":"[Double blind study of the toxicity of different doses of ethambutol given in an intermittent therapeutic regimen with streptomycin, isoniazide and ethambutol]","volume":"48","author":"Eule","year":"1973","journal-title":"Bulletin of the International Union against Tuberculosis"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0033|cit33","first-page":"153","article-title":"Preliminary results of a controlled therapeutic trail administering INH-RMP once-weekly, after- or without- an initial period of continuous treatment","volume":"84","author":"Eule","year":"1973","journal-title":"Scandinavian Journal of Respiratory Diseases. Supplementum"},{"issue":"4","key":"10.1002\/14651858.CD007545.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/ajrccm\/140.4.1001","article-title":"Random variation in tuberculin sensitivity in schoolchildren. Serial skin testing before and after preventive treatment for tuberculosis","volume":"140","author":"Felten","year":"1989","journal-title":"The American Review of Respiratory Disease"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0035|cit35","first-page":"490","article-title":"Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts","volume":"85","author":"Ferebee","year":"1962","journal-title":"The American Review of Respiratory Disease"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0036|cit36","first-page":"161","article-title":"A controlled trial of isoniazid prophylaxis in mental institutions","volume":"88","author":"Ferebee","year":"1963","journal-title":"The American Review of Respiratory Disease"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0037|cit37","first-page":"161","article-title":"Long-term effects of isoniazid prophylaxis","volume":"41","author":"Ferebee","year":"1968","journal-title":"Bulletin of the International Union against Tuberculosis"},{"issue":"3","key":"10.1002\/14651858.CD007545.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cct.2010.12.008","article-title":"Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa","volume":"32","author":"Fielding","year":"2011","journal-title":"Contemporary Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD007545.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/thx.2010.156752","article-title":"The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting","volume":"66","author":"Frigati","year":"2011","journal-title":"Thorax"},{"issue":"10","key":"10.1002\/14651858.CD007545.pub2-BIB0040|cit40","first-page":"1080","article-title":"Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis","volume":"10","author":"Gao","year":"2006","journal-title":"The International Journal of Tuberculosis and Lung disease"},{"issue":"5","key":"10.1002\/14651858.CD007545.pub2-BIB0041|cit41","first-page":"300","article-title":"[Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial]","volume":"25","author":"Geijo","year":"2007","journal-title":"Enfermedades infecciosas y microbiologia clinica"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD007545.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0041-3879(87)80021-1","article-title":"United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide","volume":"68","author":"Geiter","year":"1987","journal-title":"Tubercle"},{"issue":"6","key":"10.1002\/14651858.CD007545.pub2-BIB0043|cit43","first-page":"1065","article-title":"An assessment of the possible association of isoniazid with human cancer deaths","volume":"116","author":"Glassroth","year":"1977","journal-title":"The American Review of Respiratory Disease"},{"issue":"8","key":"10.1002\/14651858.CD007545.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archinte.1996.00440080089010","article-title":"Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease","volume":"156","author":"Graham","year":"1996","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0045|cit45","first-page":"125","article-title":"Chemoprophylaxis in high risk children-analysis of eight years' follow- up: Preliminary report","volume":"40","author":"Gupta","year":"1993","journal-title":"The Indian Journal of Tuberculosis"},{"issue":"4","key":"10.1002\/14651858.CD007545.pub2-BIB0046|cit46","first-page":"509","article-title":"Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland","volume":"35","author":"Horwitz","year":"1966","journal-title":"Bulletin of the World Health Organization"},{"issue":"5","key":"10.1002\/14651858.CD007545.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/oxfordjournals.aje.a121618","article-title":"Epidemiologic evaluation of chemoprophylaxis against tuberculosis","volume":"99","author":"Horwitz","year":"1974","journal-title":"American Journal of Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD007545.pub2-BIB0048|cit48","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0049|cit49","unstructured":"Jasmer R Bernardo J Daley C Merrifield C Blumberg H Saukkonen J Short course rifampin and pyrazinamide versus isoniazid for latent tuberculosis infection: a multicentre prospective, randomized controlled trial [abstract] American Journal of Respiratory and Critical Care Medicine 2000 A524"},{"issue":"8","key":"10.1002\/14651858.CD007545.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-137-8-200210150-00007","article-title":"Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial","volume":"137","author":"Jasmer","year":"2002","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0051|cit51","unstructured":"John GT Thomas PP Jacob CK Thomas M Kirubakaran MG Shastry JCM Double blind randomised trial of primary INAH prophylaxis in dialysis and transplant patients 12th International Congress of Nephrology. Israel 2000 13 18"},{"issue":"11","key":"10.1002\/14651858.CD007545.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/00007890-199457110-00029","article-title":"A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients","volume":"57","author":"John","year":"1994","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0053|cit53","first-page":"18","article-title":"[The role of preventive chemotherapy in the present tuberculosis epidemiology of GDR (author's translation)]","volume":"147","author":"Krebs","year":"1977","journal-title":"Zeitschrift fur Erkrankungen der Atmungsorgane"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0054|cit54","first-page":"65","article-title":"Five years of follow-up of the IUAT trial of isoniazid prophylaxis in fibrotic lesions","volume":"54","author":"Krebs","year":"1979","journal-title":"Bulletin of the International Union against Tuberculosis"},{"issue":"2","key":"10.1002\/14651858.CD007545.pub2-BIB0055|cit55","first-page":"77","article-title":"Late results of preventive chemotherapy in persons with fibrotic lesions of the lung; benefit, cost and risk (from the IUAT isoniazid prophylaxis trial)","volume":"29","author":"Krebs","year":"1980","journal-title":"Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Pneumoftiziologia"},{"issue":"14","key":"10.1002\/14651858.CD007545.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/jama.2011.436","article-title":"Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial","volume":"305","author":"Lienhardt","year":"2011","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1011214","article-title":"Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children","volume":"365","author":"Madhi","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007545.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/1740774507076937","article-title":"Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention","volume":"4","author":"Moulton","year":"2007","journal-title":"Clinical Trials (London, England)"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0060|cit60","first-page":"821","article-title":"The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis","volume":"85","author":"Mount","year":"1962","journal-title":"The American Review of Respiratory Disease"},{"issue":"5","key":"10.1002\/14651858.CD007545.pub2-BIB0061|cit61","first-page":"603","article-title":"Two controlled studies of the efficacy of isoniazid alone in preventing relapse in patients with bacteriologically quiescent pulmonary tuberculosis at the end of one year of chemotherapy","volume":"45","author":"Nazareth","year":"1971","journal-title":"Bulletin of the World Health Organization"},{"issue":"6","key":"10.1002\/14651858.CD007545.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"741","DOI":"10.5588\/ijtld.10.0392","article-title":"Results at 30 months of a randomised trial of two eight-month regimens for the treatment of tuberculosis","volume":"15","author":"Nunn","year":"2011","journal-title":"International Journal of Tuberculosis and Lung Diseases"},{"issue":"9777","key":"10.1002\/14651858.CD007545.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","article-title":"6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial","volume":"377","author":"Samandari","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD007545.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","article-title":"Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts","volume":"173","author":"Schechter","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007545.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/520983","article-title":"The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study","volume":"45","author":"Spyridis","year":"2007","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0066|cit66","first-page":"169","article-title":"Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults","volume":"41","author":"Veening","year":"1968","journal-title":"Bulletin of the International Union against Tuberculosis"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0067|cit67","unstructured":"NCT00128206 Treatment of Latent TB Infection for Jailed Persons http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00128206 (Accessed 10 May 2012)"},{"issue":"2","key":"10.1002\/14651858.CD007545.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1078345811435973","article-title":"Isoniazid versus rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence","volume":"18","author":"White","year":"2012","journal-title":"Journal of Correctional Health Care"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0069|cit69","unstructured":"Menzies D A randomized trial to compare completion and tolerability of 4 months rifampin (4 Rif) and 9 months isoniazid (9 INH) in treatment of latent TB in children http:\/\/www.controlled-trials.com\/ISRCTN53253537 Accessed 14 November 2010"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0070|cit70","unstructured":"CDC fact sheet PREVENT TB study http:\/\/www.cdc.gov\/nchhstp\/newsroom\/docs\/PREVENT-TB-Factsheet.pdf 2011 1-2 (Accessed 14 November 2011)"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0071|cit71","unstructured":"Sterling T Villarino E TBTC study 26: weekly Rifapentine + INH for 3 months versus daily INH for 9 months for the treatment of LTBI http:\/\/clinicaltrials.gov\/show\/NCT00023452 (Accessed 14 November 2011)"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0072|cit72","unstructured":"Menzies D A randomized clinical trial comparing 4RIF versus 9INH for treatment of latent tuberculosis infection (LTBI) - effectiveness http:\/\/clinicaltrials.gov\/show\/NCT00931736 (Accessed 14 November 2011)"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0073|cit73","unstructured":"Wang JY Comparing the efficacy of two preventive regimens for adult household contacts with latent tuberculosis infection http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01398618 (Accessed 15 April 2012)"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"814943","DOI":"10.1155\/2011\/814943","article-title":"Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection","volume":"2011","author":"Ahmad","year":"2011","journal-title":"Clinical and Developmental Immunology"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0075|cit75","first-page":"CD000171","article-title":"Treatment of latent tuberculosis infection in HIV infected persons","volume":"1","author":"Akolo","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD007545.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkr159","article-title":"Hepatic safety of antibiotics used in primary care","volume":"66","author":"Andrade","year":"2011","journal-title":"Journal of Antimicrobical Chemotherapy"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/thx.2009.125054","article-title":"Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4\u2005months rifampin or 9\u2005months isoniazid for latent TB","volume":"65","author":"Aspler","year":"2010","journal-title":"Thorax\u00a0"},{"issue":"3","key":"10.1002\/14651858.CD007545.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1164\/ajrccm\/142.3.725","article-title":"Diagnostic standards and classification of tuberculosis","volume":"142","author":"American Thoracic Society","year":"1990","journal-title":"American Review of Respiratory Disease"},{"issue":"31","key":"10.1002\/14651858.CD007545.pub2-BIB0079|cit79","first-page":"735","article-title":"Update: adverse event data and revised American ThoracicSociety\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection- United States, 2003","volume":"52","author":"ATS\/CDC","year":"2003","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"5","key":"10.1002\/14651858.CD007545.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3201\/eid1205.050681","article-title":"Isoniazid preventive therapy and risk for resistant tuberculosis","volume":"12","author":"Balcells","year":"2006","journal-title":"Emerging Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD007545.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE\u00a0guidelines: 3. Rating the\u00a0quality\u00a0of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD007545.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1590\/S1806-37132008001100012","article-title":"Tuberculosis and silicosis: epidemiology, diagnosis and chemoprophylaxis","volume":"34","author":"Barboza","year":"2008","journal-title":"Jornal Brasileiro de Pneumologia"},{"issue":"12","key":"10.1002\/14651858.CD007545.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrmicro2236","article-title":"The spectrum of latent tuberculosis: rethinking the biology and intervention strategies","volume":"7","author":"Barry","year":"2009","journal-title":"Nature Reviews in Microbiology"},{"issue":"3","key":"10.1002\/14651858.CD007545.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3201\/eid1703.100947","article-title":"Tuberculosis\u00a0among health care workers","volume":"17","author":"Baussano","year":"2011","journal-title":"Emerging Infectious Diseases"},{"issue":"9332","key":"10.1002\/14651858.CD007545.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","article-title":"Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial","volume":"360","author":"Benator","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD007545.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD007545.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1164\/rccm.200201-047OC","article-title":"A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment","volume":"165","author":"Bock","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007545.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/QAI.0b013e31820b07ab","article-title":"Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis","volume":"56","author":"Cattamanchi","year":"2011","journal-title":"Journal of Acquired Immune Deficiency Syndrome"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0089|cit89","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"Montly Morbidity and Mortality Weekly Report"},{"issue":"10","key":"10.1002\/14651858.CD007545.pub2-BIB0090|cit90","first-page":"214","article-title":"Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens","volume":"51","author":"Centers for Disease Control and Prevention","year":"2002","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"8","key":"10.1002\/14651858.CD007545.pub2-BIB0091|cit91","first-page":"224","article-title":"Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection-United States, 2004\u20132008","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"48","key":"10.1002\/14651858.CD007545.pub2-BIB0092|cit92","first-page":"1650","article-title":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","author":"Center for Disease Control and Prevention","year":"2011","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"10","key":"10.1002\/14651858.CD007545.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"e26199","DOI":"10.1371\/journal.pone.0026199","article-title":"High annual risk of tuberculosis infection among nursing students in south India: A cohort study","volume":"6","author":"Christopher","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1002\/14651858.CD007545.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1086\/505398","article-title":"Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection","volume":"43","author":"Cook","year":"2006","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD007545.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"e43285","DOI":"10.1371\/journal.pone.0043285","article-title":"Risk stratification of latent tuberculosis defined by combined interferon gamma release assays","volume":"7","author":"Corbiere","year":"2012","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0096|cit96","article-title":"Chapter 9: Analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Deeks","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1183\/09031936.00115110","article-title":"Interferon-\u03b3 release assays for the diagnosis of\u00a0latent\u00a0Mycobacterium\u00a0tuberculosis\u00a0infection: a systematic review and\u00a0meta-analysis","volume":"37","author":"Diel","year":"2011","journal-title":"European Respiratory Journal\u00a0"},{"issue":"6","key":"10.1002\/14651858.CD007545.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2334-10-57","article-title":"Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country","volume":"10","author":"Dyrhol-Riise","year":"2010","journal-title":"BMC Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD007545.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/427802","article-title":"Short-course therapy with rifampin plus isoniazid compared with standard therapy with isoniazid for latent tuberculosis Infection: a meta-analysis","volume":"40","author":"Ena","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0101|cit101","first-page":"A101","article-title":"Rifampin versus isoniazid for treatment of latent tuberculosis: A cost-effectiveness analysis based on a multicenter clinical trial","volume":"179","author":"Esfahani","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"9387","key":"10.1002\/14651858.CD007545.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(03)14333-4","article-title":"Tuberculosis","volume":"362","author":"Frieden","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD007545.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/422724","article-title":"Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?","volume":"39","author":"Gordin","year":"2004","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0104|cit104","unstructured":"GRADE Working Group GRADE Profiler; version 3.6 2004"},{"issue":"12","key":"10.1002\/14651858.CD007545.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE\u00a0guidelines 6. Rating the\u00a0quality\u00a0of evidence--imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7414","key":"10.1002\/14651858.CD007545.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0107|cit107","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0108|cit108","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0109|cit109","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"11","key":"10.1002\/14651858.CD007545.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","article-title":"Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection","volume":"179","author":"Holland","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"7","key":"10.1002\/14651858.CD007545.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"e22276","DOI":"10.1371\/journal.pone.0022276","article-title":"Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection","volume":"6","author":"Holland","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1002\/14651858.CD007545.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2009","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0113|cit113","first-page":"24","article-title":"Human immunodeficiency virus associated\u00a0tuberculosis\u00a0 more often due to recent infection than reactivation of\u00a0latent\u00a0infection","volume":"15","author":"Houben","year":"2011","journal-title":"International Journal of Tuberculosis and Lung Diseases"},{"issue":"23","key":"10.1002\/14651858.CD007545.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMcp021045","article-title":"Latent tuberculosis infection","volume":"347","author":"Jasmer","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD007545.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1371\/journal.pmed.0030494","article-title":"Tuberculosis among health-care workers in low- and middle-income countries: a systematic review","volume":"3","author":"Joshi","year":"2006","journal-title":"PLoS Medicine"},{"issue":"23","key":"10.1002\/14651858.CD007545.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMsa021099","article-title":"Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States","volume":"347","author":"Khan","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007545.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","article-title":"Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin","volume":"130","author":"Lardizabal","year":"2006","journal-title":"Chest"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0118|cit118","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4049\/jimmunol.0903856","article-title":"Understanding latent tuberculosis: a moving target","volume":"185","author":"Lin","year":"2010","journal-title":"Journal of Immunology"},{"issue":"4","key":"10.1002\/14651858.CD007545.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"LoBue","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2010.01751.x","article-title":"Treatment of latent tuberculosis infection: an update","volume":"15","author":"LoBue","year":"2010","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2288-11-18","article-title":"Imputation strategies for missing binary outcomes in cluster randomized trials","volume":"11","author":"Ma","year":"2011","journal-title":"BMC Medical Research Methodology\u00a0"},{"issue":"8","key":"10.1002\/14651858.CD007545.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/INF.0b013e318214b915","article-title":"The utility of an interferon gamma release assay for diagnosis of\u00a0latent\u00a0tuberculosis\u00a0infection and disease in children: a systematic review and\u00a0meta-analysis","volume":"30","author":"Machingaidze","year":"2011","journal-title":"Pediatric Infectious Disease Journal\u00a0"},{"issue":"9","key":"10.1002\/14651858.CD007545.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/adc.2006.097220","article-title":"Adherence to isoniazid preventive chemotherapy: a prospective community based study","volume":"91","author":"Marais","year":"2006","journal-title":"Archives of Disease in Childhood"},{"issue":"8","key":"10.1002\/14651858.CD007545.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1086\/444463","article-title":"National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection","volume":"41","author":"McElroy","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0126|cit126","unstructured":"Chandler J Churchill R Higgins J Lasserson T Tovey D Methodological Expectations of Cochrane Intervention Reviews (MECIR) Methodological standards for the conduct of new Cochrane Intervention Reviews. Version 2.1, 8 December 2011. Available at: http:\/\/www.editorial-unit.cochrane.org\/sites\/editorial-unit.cochrane.org\/files\/uploads\/MECIR_conduct_standards%202.1.pdf."},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1056\/NEJMe1105555","article-title":"What is thwarting tuberculosis prevention in high-burden settings?","volume":"365","author":"Nardell","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0128|cit128","unstructured":"Centers for Disease Control and Prevention TBTC Study 33. An evaluation of adherence to latent tuberculosis Infection (LTBI) treatment With 12 Doses of once weekly\u00a0rifapentine\u00a0(RPT) and isoniazid (INH) given as self-administered (SAT) versus directly-observed therapy (DOT): (iAdhere) Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT01582711?term=rifapentine&rank=15&show_desc=Y#desc 2012 (Accessed 8 May 2012)"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0129|cit129","first-page":"30","article-title":"1.6 Treatment of latent TB infection","volume-title":"NICE clinical guideline 117: Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control","author":"National Institute for Health and Clinical Excellence","year":"2011"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2648.2006.04092.x","article-title":"Directly observed therapy and tuberculosis: how can a systematic review of qualitative research contribute to improving services? A qualitative meta-synthesis","volume":"57","author":"Noyes","year":"2007","journal-title":"Journal of Advanced Nursing"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0131|cit131","unstructured":"New York City Department of Health & Mental Hygiene Bureau of Tuberculosis Control Guidelines for testing and treatment of latent tuberculosis infection Avialable at: www.nyc.gov\/html\/doh\/downloads\/pdf\/tb\/ltbi_guidelines.pdf. 2005 (Accessed 01 May 2012)"},{"issue":"22","key":"10.1002\/14651858.CD007545.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1001\/jama.293.22.2746","article-title":"Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing","volume":"293","author":"Pai","year":"2005","journal-title":"Journal of the American Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD007545.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","article-title":"Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection. An update","volume":"149","author":"Pai","year":"2008","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0134|cit134","doi-asserted-by":"crossref","unstructured":"Pai M Joshi R Narang U Zwerling A Jain V Kalantri S Predictive value of IGRA and TST in Indian health-care workers: A six-year follow up study American Journal of Respiratory and Critical Care Medicine 2011 A1198","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A1198"},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","article-title":"Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis","volume":"12","author":"Rangaka","year":"2012","journal-title":"Lancet Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD007545.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.200405-584PP","article-title":"Considering the role of four months of rifampin in the treatment of latent tuberculosis infection","volume":"170","author":"Reichman","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0137|cit137","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"3","key":"10.1002\/14651858.CD007545.pub2-BIB0138|cit138","first-page":"236","article-title":"Optimal\u00a0latent\u00a0TB control methods","volume":"9","author":"Ridzon","year":"2005","journal-title":"International Journal of Tuberculosis and Lung Diseases"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0139|cit139","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Hanbook for Systematic Review of Intervention Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184.ch12"},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1183\/09031936.00114810","article-title":"Interferon-\u03b3 release assays for the diagnosis of active\u00a0tuberculosis: a systematic review and meta-analysis","volume":"37","author":"Sester","year":"2011","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0141|cit141","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001363","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons","author":"Smieja","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD007545.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/thx.2010.138685","article-title":"Treating latent tuberculosis with rifampin: is it the cheaper option?","volume":"65","author":"Stout","year":"2010","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0143|cit143","volume-title":"Guidelines for control of Tuberculosis in Prisons","author":"Tuberculosis Coalition for Technical Assistance and the International Committee of the Red Cross","year":"2009"},{"issue":"3","key":"10.1002\/14651858.CD007545.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5588\/ijtld.11.0437","article-title":"Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews","volume":"16","author":"Werf","year":"2012","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0145|cit145","first-page":"13","article-title":"Adherence to anti-tuberculosis chemoprophylaxis and treatment in children","volume":"10","author":"Zyl","year":"2006","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"4","key":"10.1002\/14651858.CD007545.pub2-BIB0146|cit146","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003343","article-title":"Directly observed therapy for treating tuberculosis","author":"Volmink","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0147|cit147","volume-title":"International Union against Tuberculosisand Lung Disease. Anti-tuberculosis drug resistance in the world, Report no. 3","author":"World Health Organization","year":"2004"},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0148|cit148","first-page":"12","article-title":"Chapter 4: Childhood contact screening and management","volume":"11","author":"World Health Organization Stop TB Partnership Childhood TB Subgroup","year":"2007","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0149|cit149","volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency Update 2008","author":"World Health Organization","year":"2008"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0150|cit150","first-page":"1","article-title":"Key points","volume-title":"Global tuberculosis control: surveillance, planning, financing; WHO report 2010 [WHO\/HTM\/TB\/2010.7]","author":"World Health Organization","year":"2010"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0151|cit151","volume-title":"Treatment of tuberculosis. Guidelines","author":"World Health Organization","year":"2010"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0152|cit152","doi-asserted-by":"crossref","DOI":"10.30875\/52320670-en","volume-title":"WHO Report 2011: Global Tuberculosis Control","author":"World Health Organization","year":"2011"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0153|cit153","volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update","author":"World Health Organization","year":"2011"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0154|cit154","volume-title":"Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings","author":"World Health Organization","year":"2011"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0155|cit155","volume-title":"Global Tuberculosis Report","author":"World Health Organization","year":"2012"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1164\/rccm.200905-0795OC","article-title":"Short course therapy with daily rifapentine in a murine model of latent tuberculosis infection","volume":"180","author":"Zhang","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"12","key":"10.1002\/14651858.CD007545.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1086\/647944","article-title":"4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity","volume":"49","author":"Ziakas","year":"2009","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD007545.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"193923","DOI":"10.1155\/2012\/193923","article-title":"Cellular and humoral mechanisms involved in the control of tuberculosis","volume":"2012","author":"Zuniga","year":"2012","journal-title":"Clinical and Developmental Immunology"},{"issue":"1","key":"10.1002\/14651858.CD007545.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/thx.2010.143180","article-title":"Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review","volume":"67","author":"Zwerling","year":"2012","journal-title":"Thorax"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD007545.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:12:36Z","timestamp":1743984756000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007545.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Infectious Diseases Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,7,5]]},"references-count":159,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007545.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,5]]}}}